Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ).
Jiangsu Recbio Technology Co., Ltd. has convened its 2025 annual general meeting for May 28, 2026 in Taizhou, Jiangsu Province, where shareholders will review the company’s 2025 financial accounts, annual report and board work report, as well as the 2026 financial budget. The AGM agenda also covers the appointment of 2026 auditors, a remuneration scheme for directors, a 2025 profit distribution plan and a proposed change in the use of proceeds, with detailed voting arrangements and share registration deadlines set for Hong Kong investors.
Shareholders may attend the meeting in person or by proxy, subject to identity verification and compliance with proxy submission timelines, and all substantive resolutions will be decided by poll. The notice underscores governance procedures, including record dates, register closure for H shares and clarification on joint shareholder voting, reinforcing the company’s adherence to Hong Kong listing rules and formal shareholder engagement practices.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a PRC-incorporated joint stock company listed in Hong Kong under stock code 2179. Operating from Jiangsu Province, it focuses on the biopharmaceutical and medical technology sector, with its facilities located in China Medical City, a key medical high-tech district in Taizhou City.
Average Trading Volume: 8,757
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.44B
For a thorough assessment of 2179 stock, go to TipRanks’ Stock Analysis page.